Skip to main content

Advertisement

Table 1 hrHPV type-specific prevalence and cytological evaluation in cases and controls

From: Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping

  Controls (NEG/CIN1) n = 237 Cases (CIN2+) n = 79   
  Number Percent Number Percent p value^ OR (95% CI)
hrHPV positivity*
 HPV 16+ 111 46.8 48 60.8 0.038 1.8 (1.05–2.94)
 HPV 33+ 8 3.4 3 3.8 1.000 1.1 (0.32–4.04)
 HPV 31+ 28 11.8 10 12.7 0.843 1.1 (0.51–2.31)
 HPV 18+ 47 19.8 1 1.3 0.000 0.1 (0.0–0.30)
 Other hrHPV+** 43 18.1 17 21.5 0.511 1.0 (0.60–1.67)
Cytological evaluation
 Normal 148 62.5 34 43.0 0.004 0.5 (0.27–0.76)
 ASCUS+ 89 38.0 45 57.0 0.004 2.2 (1.32–3.68)
 LSIL+ 74 31.2 41 51.9 0.001 2.4 (1.42–3.99)
 HSIL+ 10 4.2 22 27.9 0.000 8.8 (3.98–19.3)
HPV and cytology  
 HPV16/18+ and ASCUS+a 24 10.3 16 20.3 0.030 2.3 (1.14–4.47)
 HPV16/18+ and LSIL+b 17 7.2 14 17.7 0.014 2.8 (1.32–5.89)
 HPV16/18+ and HSIL+c 5 2.1 5 6.3 0.128 3.1 (0.94–10.4)
 HPV16/18+ and normald 148 62.5 34 43.0 0.004 0.5 (0.27–0.76)
 HPV16/18− and ASCUS+e 65 27.4 29 36.7 0.121 1.5 (0.90–2.62)
  1. ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3)
  2. *Ranking of hrHPV genotypes according to the positive predictive values for CIN2+ (Cuzick, 2016)
  3. **Other hrHPV: HPV35, 39, 45, 51, 52, 56, 58, 59, or 68 and HPV66 (a presumptive low-risk type)
  4. ^p value of two-sided Fisher´s exact test to evaluate differences in hrHPV prevalence as well as cytology results between cases and controls
  5. aIncludes HPV16/18+ and ASCUS, LSIL, HSIL, and cervical cancer. bIncludes HPV16/18+ and LSIL, HSIL, and cervical cancer. cIncludes HPV16/18+ and HSIL and cervical cancer. dIncludes HPV16/18+ and normal cytology. eIncludes HPV16/18− and ASCUS, LSIL, HSIL, and cervical cancer. Categories a, b, and c are not mutually exclusive